Strong 2026 Guidance Points to Sustained Growth
Johnson & Johnson (J&J) recently released their fourth-quarter 2025 financial results, showcasing a robust performance that surpassed Wall Street’s expectations. Adjusted earnings came in at $2.46 per share, outperforming the anticipated $2.42 per share. The company’s revenue hit $24.56 billion, comfortably above the $24.1 billion forecast and reflecting a healthy 9.1% year-over-year growth.
Despite these impressive results, the stock experienced a minor drop of 1.7% in premarket trading—likely due to profit-taking after a remarkable 43% stock gain in 2025, marking its best performance year since 1995. Investors should take note of J&J’s subsequent move to issue a strong 2026 guidance.
Key Highlights: Pharmaceutical Division Performance
The pharmaceutical division had a mixed quarter. While some products are seeing declines, others are surging:
- Stelara: Sales crashed by 48% due to patent expiration, which negatively impacted operational growth.
- Darzalex: Revenue soared by 27%, driven by strong demand in the multiple myeloma segment.
- Tremfya: Sales surged by an impressive 68%, further strengthening the portfolio.
Looking forward, CEO Joaquin Duato expressed optimism at the JPMorgan Healthcare Conference, stating that the multiple myeloma franchise—including drugs such as Darzalex and Tecvayli—is expected to generate $25 billion in sales by 2030. Ongoing combination therapy trials for the two drugs have shown promising results, underscoring J&J’s focus on innovation.
Manufacturing Investments and Legal Challenges
To support its growth aspirations, J&J has announced plans to build two new U.S. pharmaceutical manufacturing facilities as part of a $55 billion investment. Additional investments will be disclosed later this year, highlighting the company’s confidence in meeting future demand.
However, legal challenges remain. The company continues to grapple with allegations related to its talcum powder products, specifically claims of asbestos contamination. Over 3,000 claimants in the U.K. have filed lawsuits, maintaining that J&J and its spin-off, Kenvue, bear responsibility. Both companies deny any wrongdoing.
MedTech Expansion and Future Outlook
The Medical Technology division also reported growth, with global operational sales rising by 5.6% year-over-year. Particular product categories, such as electrophysiology tools and wound closure technologies, played a significant role in boosting this segment. Acquisitions of companies such as Abiomed and Shockwave have further cemented J&J’s position as a leader in MedTech innovation.
With projected adjusted earnings of $11.53 per share and sales of $100.5 billion in 2026, Johnson & Johnson continues to outperform Wall Street’s expectations. Their diversified business model, coupled with a strong pipeline of innovative therapies, suggests the company is poised for long-term success.
Recommended Product
If you’re looking for premium solutions for skincare, check out Johnson & Johnson’s Neutrogena Hydro Boost Gel-Cream. This dermatologist-recommended skincare product hydrates and soothes your skin, making it perfect for daily routines. Learn more on their official website!
